Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$119.15 USD
+0.15 (0.13%)
Updated Sep 6, 2024 03:59 PM ET
After-Market: $119.16 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.15 USD
+0.15 (0.13%)
Updated Sep 6, 2024 03:59 PM ET
After-Market: $119.16 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Zacks News
Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath
by Zacks Equity Research
The FDA approves Ascendis' (ASND) Yorvipath (palopegteriparatide) as the first and only treatment for hypoparathyroidism in adult patients. Shares rise.
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
by Zacks Equity Research
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
by Zacks Equity Research
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
by Zacks Equity Research
Here is how AdaptHealth Corp. (AHCO) and Ascendis Pharma A/S (ASND) have performed compared to their sector so far this year.
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
by Zacks Equity Research
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
by Zacks Equity Research
Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys are part of the Zacks top Analyst Blog.
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.
Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AdaptHealth Corp. (AHCO) and Ascendis Pharma A/S (ASND) have performed compared to their sector so far this year.
Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Ascendis Pharma A/S (ASND) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
by Zacks Equity Research
Here is how Ascendis Pharma A/S (ASND) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the fourth quarter of 2023, partially offset by declining livestock product sales.
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
by Zacks Equity Research
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Does Ascendis Pharma A/S (ASND) Have the Potential to Rally 51.72% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 51.7% upside potential for Ascendis Pharma A/S (ASND). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Zoetis' (ZTS) companion animal and livestock products are expected to have driven sales in the third quarter of 2023, partially offset by declining swine product sales.
Ascendis Pharma A/S (ASND) Loses -8.26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Ascendis Pharma A/S (ASND) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Femasys (FEMY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Femasys' (FEMY) revenues in third-quarter 2023 are expected to have been driven by the higher international sales of its marketed products. Pipeline updates are expected over the earnings call.
Eton Pharma (ETON) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Eton Pharma's (ETON) revenues in the third quarter of 2023 are expected to have been driven by the sales of its marketed products.
Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Ascendis Pharma A/S (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Company News for Sep 7, 2023
by Zacks Equity Research
Companies In The News Are: AVAv, ASND, HQY, PLAB.
Wall Street Analysts Predict a 41.43% Upside in Ascendis Pharma A/S (ASND): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 41.4% in Ascendis Pharma A/S (ASND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in Ascendis Pharma A/S (ASND)? Wall Street Analysts Think 47.35%
by Zacks Equity Research
The mean of analysts' price targets for Ascendis Pharma A/S (ASND) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Pfizer (PFE) Gets FDA Nod for Growth Hormone Deficiency Drug
by Zacks Equity Research
The FDA approves Pfizer (PFE) and OPKO Health's (OPK) Ngenla to treat growth hormone deficiency in pediatric patients. The drug's commercial launch is expected this August.
Ascendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
The Zacks Analyst Blog Highlights bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals
by Zacks Equity Research
bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals are included in this Analyst Blog.